Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Marinus (MRNS)
NASDAQ:MRNS
Marinus (MRNS) Stock Price & Analysis
1,107 Followers
MRNS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.11 - $11.26
Previous Close$1.33
Volume1.31M
Average Volume (3M)2.02M
Market Cap
$73.06M
Enterprise Value-$4.25M
Total Cash (Recent Filing)$150.29M
Total Debt (Recent Filing)$72.97M
Price to Earnings (P/E)-0.5
Beta1.09
Next Earnings
Aug 08, 2024EPS Estimate
-$0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.64
Shares Outstanding54,933,774
10 Day Avg. Volume1,398,724
30 Day Avg. Volume2,016,206
Standard Deviation0.28
R-Squared0.05
Alpha-0.00481
Financial Highlights & Ratios
Price to Book (P/B)4.26
Price to Sales (P/S)10.16
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.19
Enterprise Value/Gross Profit-0.15
Enterprise Value/Ebitda0.03
Forecast
1Y Price Target
$8.56Price Target Upside543.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Marinus News
Bulls Say, Bears Say
Bulls Say
Drug Approval & Market PotentialMarinus is seeking to get ganaxolone labeled as the first treatment for refractory seizures related to TSC, potentially distinguishing it in the market.
Financial HealthMarinus held ~$113M at quarter-end, which is sufficient to reach into late 1Q’25, ensuring financial stability.
Intellectual PropertyThe USPTO has granted a new patent for the treatment of TSC with ganaxolone, providing protection through 2040.
Bears Say
Clinical Trial OutcomesSignificant clinical effect for the RAISE trial is uncertain given the miss in the interim analysis.
Financial StabilityMarinus to review cost-cutting measures to support cash balance following interim miss in RAISE.
Stock ValuationPrice Target moves from $20 to $2.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MRNS FAQ
What was Marinus’s price range in the past 12 months?
Marinus lowest stock price was $1.11 and its highest was $11.26 in the past 12 months.
What is Marinus’s market cap?
Currently, no data Available
When is Marinus’s upcoming earnings report date?
Marinus’s upcoming earnings report date is Aug 08, 2024 which is in 82 days.
How were Marinus’s earnings last quarter?
Marinus released its earnings results on May 08, 2024. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.663 by -$0.017.
Is Marinus overvalued?
According to Wall Street analysts Marinus’s price is currently Undervalued.
Does Marinus pay dividends?
Marinus does not currently pay dividends.
What is Marinus’s EPS estimate?
Marinus’s EPS estimate is -$0.59.
How many shares outstanding does Marinus have?
Marinus has 54,933,773 shares outstanding.
What happened to Marinus’s price movement after its last earnings report?
Marinus reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.663. Following the earnings report the stock price went down -8.917%.
Which hedge fund is a major shareholder of Marinus?
Among the largest hedge funds holding Marinus’s share is GMT Capital Corp. It holds Marinus’s shares valued at 15M.
---
Marinus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.56 (543.61% Upside)
$8.56 (543.61% Upside)
Blogger Sentiment
Bullish
MRNS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 393.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $214.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.99%
12-Months-Change
Fundamentals
Return on Equity
-423.43%
Trailing 12-Months
Asset Growth
-39.44%
Trailing 12-Months
Company Description
Marinus
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
---
MRNS Earnings Call
Q4 2024
0:00 / 0:00
---
MRNS Stock 12 Month Forecast
Average Price Target
$8.56
▲(543.61% Upside)
Technical Analysis
Best Analysts Covering MRNS
1 Year
1 Year Success Rate
16/35 ratings generated profit
1 Year Average Return
+5.55%
reiterated a buy rating 10 days ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 45.71% of your transactions generating a profit, with an average return of +5.55% per trade.
---